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ABSTRACT

Metabolism of Selected Antiviral Agents in Cells Infected with Drug-Resistant
and Wild-type Strains of Murine Cytomegalovirus

by
Kevin M. Okleberry, Master of Science
Utah State University, 1995
Major Professor: Dr. Reed P. Warren
Program: Toxicology
Resistance of human viral pathogens to various antiviral drugs is a serious
medical problem. Two modes of drug resistance in cytomegalovirus infections
have been observed, the first being altered (decreased) drug metabolism by the
infected cells, and the second reduced sensitivity of the viral deoxyribonucleic
acid polymerase enzyme to the active form of the drug. Mice infected with the
murine cytomegalovirus have been used extensively as an animal model for the
human cytomegalovirus, and drug-resistant strains in this model have been
identified. To better understand the mode of drug resistance of the virus, the
metabolism of two antiviral drugs, 9-(1,3-dihydroxy-2-propoxymethyl)guanine
(ganciclovir) and (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine
(cidofovir), was studied in cells infected with the virus.
The degree of resistance of the mutant virus strain to these two drugs and
also to the drug phosphonoformic acid (foscarnet) was measured in viral plaque
reduction assays. The resistant strain was 14-,4-, and 11-fold less sensitive to the
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drugs ganciclovir, foscarnet, and cidofovir, respectively, than a sensitive (wildtype) strain.
Metabolism of the antiviral drugs ganciclovir and cidofovir was studied
in C127I mouse mammary tumor cells infected with the mutant strain.
Uninfected C127I cells and C127I cells infected with the sensitive strain of murine
cytomegalovirus were used as controls. The cells were treated with tritiumlabeled ganciclovir or cidofovir and studied under a variety of parameters.
Among these were duration of treatment, multiplicity of infection, and
concentration of compound. After incubating, the cells were acid extracted and
analyzed with high-pressure liquid chromatography. The radioactivity of each
sample was measured on a scintillation counter and converted into picomoles of
drug per million cells.
No significant difference was observed between the virus strains in terms
of metabolism or catabolism of the two drugs. This effect remained constant,
even when controlling for parameters such as the amount of virus infecting each
cell, duration of treatment, or concentration of drug. Based on these results, it
appears that the mode of resistance in this mutant strain of virus to ganciclovir
and cidofovir is not due to an alteration in metabolism of these two compounds
by infected cells. Thus, it is proposed that drug resistance in this mutant strain of
virus is due to altered viral deoxyribonucleic acid polymerase function.
(62 pages)
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INTRODUCTION

The cytomegaloviruses--biology and disease
The cytomegaloviruses are ubiquitous agents that commonly infect many
species of animals as well as humans (Alford and Britt, 1990). In recent years
infections due to human cytomegalovirus (HCMV) have grown in significance
largely due to the AIDS epidemic. In healthy individuals, HCMV normally
causes an inapparent infection. However, in neonates, transplant recipients, and
immunocompromised individuals it can cause severe and sometimes fatal
complications, including retinitis, gastrointestinitis, and pneumonia (Alford and
Britt, 1990; Balfour, 1990). CMV disease has been treated mainly with the drugs
phosphonoformate (foscarnet) or nucleoside analogs, the most effective being the
guanine analog, 9-(1,3-dihydroxy-2-propoxyrnethyl)guanine, called DHPG or
ganciclovir (Balfour, 1990; Jacobson et al., 1989; Smee et al., 1983).
Other animal species typically infected with cytomegaloviruses are mice,
rats, guinea pigs, cattle, horses, and primates (Staczek, 1990; Freitas et al., 1985).
All cytomegaloviruses produce the characteristic enlargement of the infected cell
with the presence of intranuclear inclusions (Staczek, 1990). The murine
cytomegalovirus (MCMV) model has been used extensively as an in vivo model
to test drugs for use against HCMV (Duke et al., 1986; Hudson, 1979; Kern, 1991;
Smee et al., 1992; Wilson et al., 1987), and MCMV infection is considered to be
predictive for HCMV infection (Bronson et al., 1989; Duke et al., 1986; Kern,
1991).

9-(1,3-dihydroxy-2-propoxymethyl)guanine
(DHPG, ganciclovir)
DHPG is a guanine analog that exerts its antiviral effect by inhibiting the
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CMV DNA polymerase (Neyts et al., 1990), similar to the related drug acyclovir
(Elion et al., 1977; Smee et al., 1985). Both compounds are taken up by infected
cells and phosphorylated by viral and cellular enzymes (Elion et al., 1977; Biron
et al., 1985). The 5' triphosphate has been shown to be the active antiviral form
(Duke et al., 1986). However, greater concentrations of the DHPG triphosphate
are produced in CMV-infected cells than in cells treated with acyclovir (Biron et
al., 1985; Frietas et al., 1985). The general mechanism of action is the conversion
of DHPG by viral enzymes into its monophosphate form, the metabolism of the
monophosphate by cell enzymes to di-and triphosphates, then the subsequent
inhibition of the viral DNA polymerase by DHPG triphosphate (Biron et al., 1986;
Matthews and Boehme, 1988).
Originally, DHPG activity was thought to be initiated by conversion to the
monophosphate form by a cellular enzyme (Smee, 1985). Infection with
cytomegalovirus causes a general increase in host cell enzyme activity, which in
tum causes an increase in drug phosphorylation (Stinski, 1990). This was
initially believed to be the cause of increases in DI-IPG metabolism in CMVinfected cells (Smee, 1985). Later, Biron et al. (1986) found a DHPG-resistant
CMV strain that would not induce increased DHPG metabolism, suggesting the
role of a viral enzyme in drug phosphorylation. Littler et al. (1992) and Sullivan
et al. (1992) later discovered the viral gene, dubbed UL97, in cells infected with
human cytomegalovirus, which produces the enzyme responsible for the initial
step of DHPG phosphorylation.
After formation of the DHPG monophosphate (DHPGp), the cellular
guanylate kinase enzyme phosphorylates it to form DHPG diphosphate
(DHPGpp). DHPG diphosphate is then phosphorylated again to form DHPG
triphosphate (DHPGppp) (Matthews and Boehme, 1988). This compound acts as
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a 2' -deoxyguanosine triphosphate analog and binds preferentially to the virusencoded enzyme and inhibits viral DNA synthesis (Maret al., 1983). Because of
the presence of the UL97 gene, HCMV -infected human cells phosphorylate
DHPG much more efficiently than do uninfected cells. Thus, DHPG has a high
degree of selectivity, with low toxicity to uninfected cells (Andrei et al., 1991;
Freitas et al., 1985; Maret al., 1983).
In spite of the good safety profile of DHPG in cell culture and in mice,
toxicity has occurred in humans. The main problem resulting from ganciclovir
therapy is the development of bone marrow toxicity following prolonged
treatment (Balfour, 1990).

(5)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC, cidofovir)
The problem of DHPG toxicity has led to the development of newer types
of drugs, including several phosphonylmethoxyalkyl derivatives of nucleosides.
This family of drugs has a wide spectrum of activity against several DNA
viruses, including herpes simplex virus types 1 and 2, varicella-zoster virus, and
the thymidine kinase deficient (TK-) mutants of these strains (De Clerq et al.,
1986; Snoeck et al., 1988). These drugs include the compound (S)-9-(3-hydroxy-2phosphonylmethoxylpropyl)cytosine or HPMPC, which shows activity against
human, rat, and murine cytomegaloviruses (Bronson et al., 1989).
HPMPC has several advantages over DHPG. It is almost five times less
toxic as measured by selective index in cell culture (Andrei et al., 1991), and
persists in the cell much longer than DHPG (Neyts et al., 1990). Since HPMPC is
a phosphonate, it does not require initial conversion to the monophosphate form,
and thus does not require thymidine kinase activation (De Clerq et al., 1986;
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Snoeck et al., 1988). This makes it more effective against thymidine kinase
deficient (TK-) strains of herpes simplex viruses as well as DHPG-resistant
strains of human cytomegaloviruses (De Clerq, 1993). Inside the cells, HPMPC is
converted to three primary species: a choline adduct (HPMPC-choline), a
monophosphate form (HPMPCp), and a diphosphate (HPMPCpp) (Ho et al.,
1992). The HPMPC diphosphate (HPMPCpp) is thought to be the active form of
the drug (De Clerq, 1993; Ho et al., 1992), and persists much longer in infected
cells than DHPG triphosphate. This allows for more infrequent treatments.
HPMPCpp is a much more efficient inhibitor of the viral DNA polymerase than
DHPG triphosphate (Kern, 1991; Neyts et al., 1990). Another advantage of
HPMPC is that it has a higher degree of selectivity than DHPG in the sense that it
inhibits viral DNA polymerase much more efficiently than cellular DNA
polymerase (Andrei et al., 1991).
In rats infected with rat cytomegalovirus (RCMV), one treatment of
HPMPC was found to inhibit RCMV infection even when administered 7 days
prior to infection (Stals et al., 1991). Stals et al. (1991) also noted that HPMPC
was more active than DHPG against RCMV infection in terms of mortality,
histopathological analysis, and virus titers. Rabbits were protected from herpes
simplex virus type 1 viral retinitis when pretreated with HPMPC (Flares-Aguilar
et al., 1994). Otova et al. (1992) found that a single treatment of HPMPC in vitro
was sufficient for antiviral effect.
When DHPG and HPMPC were compared against each other in a mouse
model of MCMV infection, the virus was found to be more sensitive to HPMPC,
with HPMPC being approximately 10 times more effective than DHPG in terms
of increasing the number of MCMV-infected mice surviving after treatment
(Smee et al., 1992). In MCMV-infected immunosuppressed mice, HPMPC was
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shown to have a therapeutic index 50-fold greater than DHPG (Smee et al., 1992).
HPMPC was more effective than DHPG in preventing mortality in both
immunocompetent and immunosuppressed mice (Neyts et al., 1993). In vitro,
several strains of HCMV and one strain of MCMV have been shown to be 5- to
40-fold more sensitive to HPMPC than to DHPG (Kern, 1991).
The main toxic side effect of HPMPC is nephrotoxicity (Neyts and De
Clerq, 1993). Kern (1991) noted that HPMPC can accumulate in the kidneys of
mice. HPMPC nephrotoxicity has been observed in humans after two weekly
doses of 10 mg/kg, and was reversible after cessation of therapy (Neyts and De
Clerq, 1993). Nephrotoxicity has been reduced by the conversion of HPMPC into
its cyclic cogener (Hitchcock et al., 1995).

Phosphonoformic acid (foscarnet)
Foscarnet is an analog of pyrophosphate, which reversibly and
noncompetitively inhibits the cytomegalovirus (CMV) DNA polymerase
(Balfour, 1990), as well as other viral DNA and RNA ·polymerases and reverse
transcriptase (Oberg, 1989). As a result, foscamet has in vitro antiviral activity
against several species of viruses, including virtually all herpesviruses, human
immunodeficency virus (HIV), and hepatitis B virus (Oberg, 1989; Fletcher et al.,
1994). It is currently approved for use against human CMV retinitis in
immunocompromised individuals.
Treatment with foscarnet has been shown to be effective in reducing or
stabiliz~ng

the number of CMV retinal lesions in immunocompromised patients

as well as reducing viruria and viremia (Jacobson et al., 1989). Ringden et al.
(1985) reported that after foscarnet treatment, clinical improvement was seen in
69% of transplant patients infected with CMV. Oberg (1989) reported that
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several other researchers have noted improvement in CMV-infected AIDS
patients. As for treatment of HIV infection, Fletcher et al. (1994) reported that
several patients had increased amounts of CD4+ lymphocytes and decreased
mean amounts of HIV antigen in the blood. Against murine cytomegalovirus,
foscarnet treatment significantly reduced the mortality rate in infected mice, as
well as viral titers in infected organs (Overall et al., 1976).
The main adverse effect of foscarnet treatment is renal dysfunction
(Balfour, 1990), although hydration may reduce this effect (Taburet et al., 1992).
Foscarnet acts as a chelating agent for calcium and has been linked to seizures,
arrhythmias, and fatal cases of hypocalcemia (Jacobson et al., 1991). Up to 28% of
the cumulative dose is deposited in bone tissue (Balfour, 1990).

Viral resistance to antiviral drugs
Prolonged therapy with DHPG has been associated with the formation of
DHPG-resistant strains of cytomegalovirus (Drew et al., 1991; Erice et al, 1989). It
is estimated that 10-15% of AIDS patients with CMV retinitis who receive longterm ganciclovir therapy develop resistant strains of HCMV (Biron, 1991). Two
main modes of cytomegalovirus resistance to DHPG have been reported. Lurain
et al. (1992) and Sullivan et al. (1992) reported that point mutations in HCMV
gene UL97 produced a resistant viral strain. This is due to decreased DHPG
phosphorylation in infected cells. Both investigators reported that resistance due
to point mutations in the HCMV DNA polymerase also conferred crossresista~ce

to DHPG and HPMPC (Lurain et al., 1992; Sullivan et al., 1993). Lurain

et al. (1994) reported that HCMV DNA containing a UL97 mutation could be
transferred to a sensitive strain, thus conferring resistance to DHPG.
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Resistance to HPMPC in human and murine cytomegaloviruses has
already been reported both in laboratory strains (Smee et a1., 1995; Sullivan et al.,
1993) and from CMV-infected patients treated with ganciclovir (Drew et al., 1991;

Erice et al., 1989; Stanat et al., 1991). Cross-resistance between DHPG, HPMPC,
and other drugs in human strains has also been observed (Lurain et al., 1992).
Resistance to foscarnet has also been noted in clinical (Tatarowicz et al.,
1992) as well as in laboratory virus strains (Sullivan and Coen, 1991). Some of

these strains have shown cross-resistance to DHPG and HPMPC (Sullivan and
Coen, 1991; Tatarowicz et al., 1992). Jacobson et al. (1991) observed that foscarnet
tr.erapy was effective in patients with ganciclovir-resistant cytomegalovirus
retinitis. Since foscarnet does not require intracellular phosphorylation to exert
it5 antiviral effect (Oberg, 1989), it has been postulated that resistance to foscamet
is indicative of a mutation in the viral DNA polymerase (Tatarowicz et al., 1992).
Smee et al. (1995) developed a murine cytomegalovirus strain that was
ctoss-resistant to DHPG, HPMPC, and foscarnet. In order to better understand
H.e mode of drug resistance of this murine virus, the studies presented in this
tresis were conducted. To date, no results have been published on the
p.1osphorylation of DHPG and HPMPC in murine cytomegalovirus-infected
cElls. The results presented here shed light on the mode of drug resistance of this
mutant strain of MCMV.
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JUSTIFICATION OF RESEARCH
The problem of the development of viral drug resistance during
prolonged therapy has created the need for models to determine the modes of
resistance to these drugs, and to develop strategies to overcome or delay the
emergence of drug-resistant virus strains. Researchers have determined that
HCMV resistance to nucleoside and nucleotide analog drugs is usually due to
one or both of two mechanisms: an alteration resulting in the decrease in the
uptake or phosphorylation of the compound (Lurain et al., 1992; Sullivan et al.,
1993), or a mutation in the viral DNA polymerase which causes lowered affinity
for the active form of the drug to this enzyme (Lurain et al., 1992; Ochiai et al,
1992).
The model of HCMV infection chosen for this research is MCMV. Smee et
al. (1995) developed a strain of MCMV resistant to DHPG, HPMPC, and
foscarnet. The reason why this virus is resistant to these antiviral drugs has not
been previously e~plored. Because HCMV and MCMV are closely related, crossresistance to DHPG, HPMPC, and other similar drugs by the mutant strain of
MCMV is assumed to be due to differences in either drug metabolism or
inhibition of DNA polymerization, or both. The first hypothesis can be tested by
showing significantly lower amounts of active drug forms are produced in cells
infected by the resistant virus as compared to the sensitive virus. To do so, the
amounts of DHPG triphosphate (DHPGppp) and HPMPC diphosphate
(HPMP_C pp) (the active antiviral drug metabolites) that are produced by the
infected cells were compared. Negative results, which in this case would be no
significant difference between sensitive and resistant virus strains in terms of
affecting drug metabolism, indicate a different mode of resistance.

9

The second hypothesis is that the resistance is due to a mutation in the
MCMV DNA polymerase. Lower affinity of the resistant polymerase for active
forms of the drugs as compared to the sensitive polymerase would support this
hypothesis. Also supporting this hypothesis is the fact that the resistant strain is
cross-resistant to foscamet, which does not require initial phosphorylation to be
active (Balfour, 1990), and is a known inhibitor of CMV DNA polymerase
(Oberg, 1989).
The first hypothesis, which involved studying drug metabolism in cells
infected by resistant and sensitive viruses, was investigated in detail. As this
research project progressed, it became apparent that it would not be possible to
test this second hypothesis, due to a lack of time and funding. Therefore, only the
first hypothesis was tested. As a result, this thesis answers only one part of the
question of drug resistance, that of whether the resistance is due to decreases in
metabolism of the antiviral drugs by the infected cells.
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MATERIALS AND METHODS

Compounds and solutions
Ganciclovir was manufactured by Syntex (Palo Alto, CA) and obtained
from a local pharmacy. HPMPC was obtained from Gilead Sciences (Foster City,
CA). Foscarnet was obtained from Sigma (St. Louis, MO). 3H-labeled DHPG
and HPMPC were purchased from Moravek Biochemicals (Brea, CA). The
DHPG was labeled on the guanine methyl group, while the HPMPC was labeled
on the hydrogen atom of the fifth carbon of the cytosine. The structures of all
three compounds are shown in Figure 1.
The high-pressure liquid chromatography buffer was prepared using
HPLC-grade ammonium phosphate

(JT Baker, Phillipsburg, NJ). Perchloric acid

was obtained from Mallinckrodt (Paris, KY), and potassium hydroxide and
imidazole were obtained from Fisher Scientific (Fair Lawn, NJ).
The high-pressure liquid chromatography apparatus consisted of a Waters
model510 high-pressure liquid chromatograph, with the gradient being
controlled by a Waters Lambda-Max Model481 automatic gradient controller
(San Francisco, CA). The column used was a Whatman (Clifton, NJ) 25-cm
partisil10X strong anion exchange column. Spectrophotometric data from the
liquid chromatographer were obtained from a Waters Lambda-Max model481
LC spectrophotometer and were graphed using a Shimadzu CR 601 chromatopac
integrator (Columbia, MD). Fractions from the HPLC were collected in 7-ml
polyethylene scintillation vials (Kimble, Vineland, NJ) using a Pharmacia Frac
100 fraction collector (Piscathaway, NJ), and the liquid fractions were suspended
in Beckman Ready-Safe scintillation fluid (Beckman, Fullerton, CA).
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Fig. 1. Chemical structures of antiviral compounds used.
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The radioactive samples were analyzed using a Beckman LC 5801 scintillation
counter.

Virus and cells
The sensitive, "wild-type" Smith strain of MCMV (hereafter referred to as
the "sensitive" strain) was obtained from American Type Culture Collection
(Rockville, MD). The plaque-purified resistant strain, referred to as GCV-r
MCMV in Smee et al. (1995), was developed by propagating the sensitive MCMV
strain in increasing concentrations of DHPG. This virus shows resistance to
DHPG, HPMPC, and foscarnet. C127I cells, derived from mouse mammary
tumors, were obtained from ATCC. The cells were grown in 55-cm2 petri dishes,
the resistance assays were performed in 12-well tissue culture plates, and the
labeling experiments were done in 25-cm2 tissue culture flasks. All plasticware
was obtained from Corning, Inc. (Corning, NY). The cells were grown in
Dulbecco's minimum essential medium (DMEM) with 5 mM HEPES buffer
(Sigma) and 10% fetal bovine serum added (Hyclone Laboratories, Logan, UT).
Virus plaques were counted using a Plaque Viewer (Bellco Labs, Vineland, NJ).
SeaPlaque agarose was obtained from FMC Bioproducts (Rockland, ME).

Preparation of virus pools
Two large pools of virus, one of the mutant strain (resistant) and one of
the wild-type or Smith strain (sensitive), were prepared. Four 150-cm 2 and two
75-an 2 tissue-culture flasks were seeded with C127I cells in DMEM 10% FBS and
the cells were grown at 370 C until confluent. When confluent, two 150-cm2
flasks and one 75-cm 2 flask were infected with either the resistant virus or the
sensitive virus. Each pool of virus was suspended in 50 ml of DMEM 2% FBS at a
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concentration of 1000 plaque-forming units (PFU) per ml, and 20 ml was added
to each 150-cm2 flask and 10 ml was added to the 75-cm2 flask.
After 3 days of incubation at 370 C, the media were removed and replaced
with fresh DMEM 2% FBS at the same volume per flask. After a total of seven
days of incubation, the infected cells were harvested with the media, pooled, and
disrupted by sonication for 1 min. The pools were then dispensed into cryovials
at 1.0 ml per vial and frozen at -700 C.
The virus pools were titrated using a crystal violet plaque assay. Two 12well tissue culture plates were seeded with C1271 cells, grown to confluency, and
infected with 0.5 ml per well of diluted virus, ranging from 10-1 to 10-6, two
wells per dilution. The virus was allowed to adsorb for 1 h and 15 min, removed,
and the cells were overlaid with DMEM 2% FBS, 0.1% NaHC03, with 0.5%
agarose added, and the agarose was allowed to harden at 40 C for 5-10 min.
After 7-8 days of incubation at 37° C, the cells were fixed for 15 min with 10%
phosphate-buffered formalin. The formalin and agarose were removed, and the
cells were stained in a solution of 20% ethanol containing 0.2% crystal violet. To
obtain the virus titer, the clear plaques in the cell monolayers, each representing
one virus particle, were counted on a Plaque Viewer and multiplied by the
dilution factor and a conversion factor of 12.65. The conversion factor takes into
account the actual volume of liquid that touches the cell monolayer, since most of
the virus in the medium does not adsorb to the cell surface, and is used in
accurately determining PFU per ml of virus-containing medium. This titration
procedtire was repeated three times for each virus pool, and the results were
averaged to yield the titer.
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Determination of virus resistance
The relative sensitivities of both pools of virus to the drugs DHPG,
HPMPC and foscarnet were determined using a plaque-reduction assay
described by Smee et al. (1995). Three 12-well plates were used for each drug
tested, one and one-half plates for each virus strain. The plates were seeded with
C127I cells in DMEM 10% FBS and grown until confluent. The cells were
infected with enough virus to produce approximately 100 plaques per well. For
the resistant virus, a 1:10,000 dilution was used, while the sensitive virus used a
1:5000 dilution. One-half milliliter of virus was added to each well, one and onehalf plates being infected with the resistant virus, with the other one and one-half
being infected with the sensitive virus. The virus was adsorbed at 37° C for 1 h
and 15 min.
After adsorption, the virus was then removed and replaced with DMEM
2% FBS, 0.1 % NaHC03, 0.5% agarose containing eight serial1:2 dilutions of the
drug tested. Two wells per concentration were used, with two wells left
untreated as a virus control. The concentrations of drug varied, depending on
the virus strain: For DHPG, the concentrations used against the resistant virus
ranged from 160 to 1.25 IJ.M, while the concentrations used against the sensitive
virus ranged from 40 to 0.3125 j.!M; for HPMPC, the resistant virus was tested
against concentrations of 16.0 to 0.125 IJ.M, while the sensitive virus was tested
against concentrations of 4.0 to 0.03125 j.!M; for foscamet, the resistant virus was
tested against concentrations of 1200 to 12.51J.M, and the sensitive virus was
tested against concentrations of 400 to 3.125 IJ.M. The plates were incubated for 7
or 8 days, and then fixed, stained, and the plaques counted as described
previously. The average plaque count for each virus concentration was
expressed as a percentage of the control, and the 50% effective concentration
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(ECso) values were estimated by plotting percent of plaques inhibited versus
drug concentration on semilog graph paper. This trial was repeated three times
for each virus against each drug, and then an average value with standard
deviations was obtained for each one.

Determination of metabolism of DHPG and
HP MPC in cells
To determine the metabolism of these drugs in infected and uninfected
C127I cells, a basic high-pressure liquid chromatography (HPLC) procedure
similar to those previously described (Freitas et al., 1985; Smee et al., 1985; Smee
and Matthews, 1986) was used. Five different experiments were performed that
addressed the variables of different concentrations of drug, multiplicity of
infection and time on drug metabolism, and the catabolism of phosphorylated
drugs inside the cell. The HPLC procedure is described on pages 21 and 22.

Effect of different concentrations of drug on
viral metabolism
In the first experiment, the effect of different concentrations of drug on
virus-induced phosphorylation wa~ examined. Eighteen 25-cm2 flasks were
seeded with C127I cells and grown to confluency. When confluent, the flasks
were separated into three sets of six flasks each. One set was infected with the
resistant strain, one with the sensitive strain, and one was left as an uninfected
control. The virus was suspended in DMEM 2% FBS, 5 mM HEPES at a
multipl~city

of infection (MOl) of 2.0 PFU per cell, and 1.2 ml of medium was

added to each flask. The virus was adsorbed for 1 h and 15 min.
DHPG was diluted in DMEM to concentrations of 30, 10, and 3.0 ~M, and
HPMPC was diluted to concentrations of 3.0, 1.0, and 0.3 J.LM. Twenty JJ.Ci/ml of
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3H-labeled compound was added to each dilution for a total activity of 24 ~Ci
per flask, (1.2 ml of medi urn containing labeled drug was added to each flask),
and the cells were incubated for 24 hat 370 C.
The cells were harvested by removing the radioactive media, rinsing 1X
with 2.0 ml of DMEM without FBS added, adding 0.5 ml of 3.5% perchloric acid,
and incubating at 40 C for 5 min. After incubation, the flasks were placed on end
and the acid was neutralized with 0.25 ml of 1.0 N KOH with 0.2 M imidazole
(1,3-diazo-2,4-cyclopentadiene) added. The supernatant was mixed in the flask
briefly and then removed and frozen at -700 C.

Effect of multiplicity of infection (MOl)
on drug phosphorylation
The second experiment dealt with the effect of MOl on drug
phosphorylation. MOl refers to the number of infectious virus particles to the
number of cells. For example, an MOl of 1.0 means one virus particle per cell.
Eighteen 25-cm 2 tissue culture flasks were seeded with C127I cells and grown to
confluency. At the time of infection, they were separated into two groups of
eight flasks each, with two flasks left over. Both groups were infected with either
the resistant virus or the sensitive virus suspended in DMEM containing 10%
FBS and 5 mM HEPES buffer. In each of the infected groups, two flasks were
infected at an MOl of 3.0, 1.0, 0.3, or 0.1 PFU I cell, and the virus was allowed to
adsorb for 1 h and 15 min. The two remaining flasks were used as uninfected
controls.
After adsorption, the virus was removed and the flasks were arranged
into two groups of nine flasks each. Each group contained one flask of each virus
at each MOl and an uninfected control. One group was treated with 10 JlM
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DHPG with 20 J,.LCi/ml3H-labeled DHPG added, while the other was treated
with 1.0 J..LM HPMPC with 20 J,.LCi/ml of 3H-labeled HPMPC added. The cells
were then incubated for 24 h at 370 C, and then harvested using the perchloric
acid-KOH/imidazole procedure and frozen at -700 C.

24-hour time-course metabolism experiment
This experiment was done to determine the differences, if any, between
the phosphorylation of DHPG and HPMPC in cells infected with the two virus
strains over a period of 24 h. C127I cells were seeded into 36 25-cm2 tissue
culture flasks and grown to confluency. Of the 36 total flasks, 12 were infected
with the resistant virus strain at an MOl of 1.0 PFU I cell, while 12 were infected
with the sensitive virus strain at the same MOl, and 12 were left uninfected as
controls. The virus was adsorbed the usual time of 1 hand 15 min.
After adsorption, the virus was removed and flasks were divided into two
sets of 18, each set containing 6 flasks from the three infection groups. One set of
18 flasks was treated with DHPG at 10 J..LM and the other was treated with
HPMPC at 1.0 J..LM. The flasks were incubated at 370 C.
At time points of 1, 2, 4, 6, 12, and 24 h postinfection, three flasks from
each drug treatment group (one resistant-infected, one sensitive-infected, and
one uninfected) were harvested using the perchloric acid-KOH/imidazole
procedure and the supernatants were frozen at -700 C.

Dephosphorylation and excretion of drugs
This experiment described the difference between the catabolism of the
drugs. The experiment was organized the same way as the previously described
experiment; however, the drugs were left on the cells for 24 h of incubation, and
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then the media were removed and the cells were washed 2X with 2.0 ml of
DMEM and refed with 1.2 ml of drug-free DMEM 10% FBS. Cell supernatants
were harvested using the perchloric acid/KOH method at 0, 1, 2, 4, 6, 12, and 24
h after the removal of the drugs, for a total of six per time point. At the same
time points, 600-~l samples of the cell media were removed and analyzed for
radioactivity. The cell supernatants were frozen at -70° C.

96-hour time-course metabolism experiment
In this experiment, the phosphorylation of DHPG and HPMPC was
measured over a period of 4 days. Because of the possibility of severe
cytotoxicity due to the virus infection affecting the amount of phosphorylated
drug produced, a duplicate set of flasks was prepared for this experiment, and
cell counts were performed at each time point.
Forty-eight 25-cm2 flasks were seeded with C127I cells and grown to
confluency. The flasks were divided into three groups of 16 flasks each. One
group was infected with resistant virus at an MOl of 1.0 PFU I cell, another group
was infected with sensitive virus at the same MOl, and the third group was left
uninfected as a control. Each of the flasks received 1.2 ml of medium, and the
virus was adsorbed for the standard period of time.
After adsorption, the virus was removed and the flasks were divided in to
four groups of 12 flasks, each with 4 resistant-infected, 4 sensitive-infected, and 4
uninfected flasks. One group was treated with 1.2 ml/flask of HPMPC at 1.0 ~M
with 20_ ~Ci/ml of 3H-labeled HPMPC added, while another was treated with 1.2
ml/flask of DHPG at 10 ~M with 20 ~Ci/ml of 3H-lab€led DHPG added. The
two remaining groups were treated either with 1.2 ml of 1.0 ~M HPMPC or 1.2
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ml of 10 ~M DHPG with no radioactive compounds added. All were incubated
at 370 C.
At time points of 24, 48, 72, and 96 h postinfection, one set of three flasks
from each group, each containing one infected with resistant virus, one infected
with sensitive virus, and one uninfected control, was removed. The flasks
treated with the 3H-labeled compounds were harvested using the perchloric
acid-KOH/imidazole procedure and the supernatants were frozen at -70° C. The
controls for determining cell numbers at each time point were harvested by
removing the media, adding 1.0 ml of trypsin per flask, allowing the cells to
detach and then resuspending them in 4.0 ml of DMEM 10% FBS. The cells were
counted microscopically using a hemocytometer, and two counts were
performed per sample.

Virus yield assay
To determine the effect of the drugs HPMPC and DHPG on virus yield in
cells infected with sensitive or resistant virus, an assay that measured the levels
of virus over a period of 4 days was developed, based on an assay previously
described by Smee et al. (1995). Four 12-well plates were seeded with C127I cells
and allowed to grow to confluency. Each plate was divided in half (6 wells) and
one half was infected with 0.5 ml of resistant virus while the other half was
infected with 0.5 ml of sensitive virus. Both virus strains were suspended in
DMEM containing 10% FBS and 5 mM HEPES, and both were infected at an MOl
of 1.0 PFU /ml.
After virus adsorption, the virus was removed and each plate was divided
into three sections of four wells, each section with two wells of resistant virusinfected cells and two wells of sensitive virus-infected cells. On each plate, one
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section was treated with 10 J.!M DHPG, one was treated with 1.0 JJ.M HPMPC,
and one was placebo-treated with media only. The drugs were suspended in
DMEM 10% FBS with 5 mM HEPES added, and 1.0 ml of solution was used per
well. The plates were incubated at 370 C.
At 24,48, 72, and 96 h postinfection, one plate at each time was removed
and frozen at -200 C. The virus was harvested by removing the treated plates
from the freezer and allowing them to thaw slightly. The frozen media were
swirled in the wells to scrape the cells from the bottom, and then the samples
were allowed to thaw completely. Each plate had two wells with the same
samples, and the contents of these two wells were pooled in a test tube and
sonicated for 1 min. From this tube 111 JJ.l was removed and diluted in 1.0 ml of
DMEM, and then serially diluted to 10-6 for the 24-h samples, and 1o-7 for the
rest of the time points.
Prior to harvesting the virus from each time point, three 12-well plates
were seeded with C1271 cells and grown to confluency. Each plate was divided
in half and then 0.5 ml of each virus dilution was placed in a well, for a total of
six wells per sample, two samples per plate. The virus was adsorbed for 1 hand
15 min, removed, and the cells were overlaid with DMEM 2% PBS, 0.5% agarose.
The plates were incubated for 7 days and then fixed with formalin and stained
with crystal violet as per previous procedures.
The plaques were counted using the Plaque Viewer, and the titers for each
sample were obtained by multiplying the number of plaques by the dilution
factor and by the conversion factor as described on page 13.
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High-pressure liquid chromatography analysis
of the frozen supernatants
HPLC analysis of the samples was performed using a modified procedure
of one described in Smee et al. (1985). The frozen radioactive supernatants were
thawed, gently vortexed, and filtered using a 0.45-J,lm syringe-type filter (Gelman
Scientific, Ann Arbor, MI) designed for HPLC samples. Five hundred microliters
(500 J.ll} of each sample were injected into the HPLC. The HPLC buffer was
prepared from ammonium phosphate (J. T. Baker, Phillipsburg, NJ) at
concentrations of 1.0 M and 0.01 M, pH-adjusted to 3.5, and filtered through
Whatman 0.45 micron filters. The DHPG-treated cell extracts were separated on
a linear gradient starting at 0.01 M am.m onium phosphate, pH 3.5, and ending at
1.0 M ammonium phosphate, pH 3.5, at 35 min. The gradient was sustained at
1.0 M ammonium phosphate for another 5 min, and then was reduced to 0.01 M
using a linear gradient for 5 min. Total running time for the DHPG gradient was
45 min.
The HPMPC-containing samples were separated using the same
concentrations of ammonium phosphate, but different run times. The initial
linear gradient lasted for 45 min. The 1.0 M ammonium phosphate plateau was
sustained for 5 min, and then the concentration was returned to 0.01 M
ammonium phosphate using a linear gradient lasting for 4 min. The flow rate of
the HPLC pumps was set at 1.0 ml per min, and 1-min fractions were collected in
the scintillation vials.
During the separation, the UV absorbance (280 nm wavelength) of the
various fractions was measured by the spectrophotometer and the resulting
peaks were recorded by the integrator.
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After chromatographic separation of the samples, 4.0 ml of scintillation
fluid were added to each vial, mixed with the sample, and then the radioactivity
of each fraction was determined using the scintillation counter. The counter
provided the counts per minute (CPM) of each 1-min fraction.
The amount of pmol/106 cells was determined by a procedure adapted
from Smee et al. (1985). Briefly, it was first necessary to determine the average
number of cells analyzed and the specific radioactivity of each drug used
(CPM/picomole). To obtain cell counts, four 25-cm2 tissue culture flasks were
seeded with C127I cells and grown to confluency. The cells were trypsinized,
suspended in DMEM, and counted microscopically using a hemocytometer.
Each sample was counted twice, and the counts were averaged to yield 2.7 X 106
cells. This number was used for all 0-24 h metabolism experiments as being
representative of the amount of cells in a confluent 25-cm2 flask.
After each sample was counted on the scintillation counter, the peaks
were identified and quantified by adding the total counts per minute in each
peak, minus a background value of 20 counts per minute. These peak totals were
converted into picomoles using a conversion factor. This conversion factor was
obtained by removing 10 J.ll of medium from each sample flask immediately
prior to harvesting the cells. The 10 J!l were suspended in 5 ml of scintillation
fluid and counted. Because the amount of labeled and unlabeled compound
added to the media was the same for each sample, the amount of radioactivity in
each sample was considered to be directly proportional to the amount of
unlabeled compound in the media. Thus, 10 Jll of a 10 JlM solution had a total of
100 picomoles of unlabeled compound. By counting the amount of radioactivity
in each 10-J.l.l sample, and expressing this as CPM/pmol, the amount of
picomoles in each peak was determined by multiplying the total CPM/ peak by

23
this ratio. The product was then divided by 2.7 to express it in terms of
pmol/106 cells. The resulting values of pmol/106 cells were plotted versus time,
concentration of drug, or multiplicity of infection.
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RESULTS

Determination of virus resistance
Plaque reduction assays were conducted to establish that the plaquepurified drug-resistant virus was less sensitive to three antiviral compounds than
the sensitive (wild-type) virus. Against the drug DHPG, the resistant virus had
an average 50% effective concentration (ECso) of 72
virus had an ECso of 5.1

~M,

~M,

while the sensitive

a 14-fold difference. For HPMPC, the ECso of the

resistant virus was 2.7 ~M versus an ECso of 0.24

~M

for the sensitive virus, an

11-fold difference. The ECsos for the drug foscarnet against the resistant and
sensitive virus strains were 627 and 141

~M,

respectively, a 4-fold difference.

The average ECsos of the resistant and sensitive virus strains were
compared for each compound using a two-tailed t-test with the InStat® statistical
program, and the differences were determined to be extremely significant
(p<0.001) . The ECsos for the three drugs tested versus both the resistant and
sensitive strains were similar to the values reported previously by Smee et al.
(1995) (the former drug-resistant virus was not plaque-purified). The resistance
data are summarized in Table 1.

Drug metabolism experiments
Phosphorylation of DHPG and HPMPC was initially studied under a
defined set of experimental conditions. These parameters were a multiplicity of
infection of 1.0, a DHPG concentration of 10 ~Moran HPMPC concentration of
1.0 ~M, and an incubation time of 24 h. Analysis of drug metabolites was made
byHPLC.
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Table 1
Fifty-percent effective concentration (EC5o) values (!J.M) of DHPG, HPMPC, and
foscarnet against resistant and sensitive virus strains, determined by plaquereduction assays in C127I cells

Resistant virus
Sensitive virus

DHPG
72 ± 2.0 a (14.1) b
5.1 + 2.4

HPMPC
2.7 + 0.4 (11.3) b
0.24 + 0.04

Foscamet
627 ± 90 (4.4) b
141 + 10

a Mean+ standard deviation (three independent assays).
b p<0.001.
For the drug DHPG, the unphosphorylated parent compound was eluted
4 to 8 min postinjection (Fig. 2). The monophosphate form of DHPG (DHPGp)
was eluted immediately afterwards, at 9-13 min postinjection. The diphosphate
form (DHPGpp) was eluted between 23-27 min postinjection, and its peak was
generally larger than the monophosphate peak. The triphosphate form
(DHPGppp), which is the active form of the drug, was eluted at 38-42 min
postinjection. The averages for three sample sets treated with DHPG showed
that the sensitive virus-infected samples produced about the same amount of the
active forms of compounds as the resistant-infected samples, while the
uninfected control samples consistently produced the lowest amounts (Table 2).
Table 2
Average amounts of phosphorylated species of DHPG (pmol/106 cells)
produced by cells infected with resistant, sensitive, or no virus at an MOl of 1.0
and treated with 10 !J.M DHPG for 24 hours

Resistant virus
Sensitive virus
Uninfected

DHPGp

DHPGpp

DHPGppp

0.221 ± 0.030
0.037 ± 0.012
0.019 + 0.012

0.166 ± 0.099
0.110 + 0.047
0.066 + 0.013

0.147 + 0.011
0.154 + 0.004
0.122 + 0.023
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The DHPG monophosphate peak was usually quite small in relation to the
other peaks, except in cells infected with resistant virus. The monophosphate
peak was approximately 16% the size of the triphosphate peak in uninfected
cells, 24% in sensitive-infected cells, and 150% in resistant-infected cells. The
resistant-infected cells also produced more of the diphosphate than of the
triphosphate. On average, the diphosphate peak was approximately 54% as large
as the triphosphate peak in uninfected cells, 71% as large in sensitiveinfectedcells, and 113% as large in the resistant-infected cells. There was much
less variation between experiments in the amount of triphosphate produced by
the cells, as compared to the amounts of the other phosphorylated species.
The parent (unphosphorylated) form of HPMPC was eluted between 4
and 9 min postinjection (Fig. 3). Immediately after elution of the parent
compound, a relatively large peak of HPMPC-choline adduct was eluted,
between 10 and 14 min postinjection. A monophosphate form of HPMPC
(HPMPCp) was eluted between 19-23 min, and the diphosphate or active form of
the drug (HPMPCpp) was eluted at 33-36 min postinjection.
In general, no significant differences in HPMPC metabolism were noted
between cells infected with the two types of virus, and the uninfected control
cells (Table 3). Cells infected with the resistant virus produced slightly more of
the phosphorylated species than cells infected with the sensitive strain or the
uninfected cells. The time of elution for each phosphorylated specie of
compound also remained the same. The HPMPC-choline peak was, on average,
3.4, 3, and 3.4 times larger than the diphosphate peak produced by the resistantinfected, sensitive-infected, and uninfected cells, respectively. The
monophosphate peak was usually the smallest peak produced, with it being 44%,
36%, and 70% of the diphosphate peaks produced by resistant, sensitive, and
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Table 3
Average amounts of phosphorylated species of HPMPC (pmol/ 106 cells)
produced by cells infected with resistant, sensitive, or no virus at an MOl of 1.0
and treated with 1.0 J..LM HPMPC for 24 hours
HPMPC -choline
Resistant virus
Sensitive virus
Uninfected

0.108 ± 0.046
0.108 + 0.035
0.093 + 0.022

HPMPCp
0.014 ± 0.001
0.013 + 0.002
0.018 + 0.006

HPMPCpp
0.032 + 0.009
0.036 + 0.008
0.027 + 0.016

uninfected samples, respectively. Like the HPMPC-choline peak, the resistantinfected, sensitive-infected, and uninfected cells produced roughly equal
amounts of HPMPCp and HPMPCpp (Table 3).

Dose-dependent phosphorylation of drugs
In this experiment, cells were infected with an MOI of 2, and treated with
DHPG at concentrations of 30, 10, or 3.0 J..LM; or HPMPC at concentrations of 3.0,
1.0 or 0.3 J..LM and incubated for 24 h. At 30 J..LM DHPG, the infected cells
produced 0.597 pmol of active DHPGppp per 106 cells, as compared to 0.418
pmol of DHPGppp produced by cells infected with the sensitive strain and 0.211
pmol of DHPGppp produced by uninfected cells (Fig. 4). The amount of
triphosphate produced by the infected and uninfected cells rose linearly in
proportion to the concentration of DHPG present in the media.
A similar effect was noted with HPMPC, although the sensitive-infected
and uninfected cells produced similar amounts of HPMPC diphosphate. At 3.0
J..LM of HPMPC, the resistant-infected cells produced 0.255 pmol/106 cells, the
sensitive-infected produced 0.148 pmol/106 cells, and the uninfected cells
produced 0.134 pmol/106 cells (Fig. 5).
Cells infected with the resistant virus produced slightly more of the active
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forms of both DHPG and HPMPC at all three concentrations used. However,
this was not considered significantly larger than amounts of metabolites
produced in cells infected with the sensitive virus, based on previous work with
resistant strains (Biron et al., 1986). With both DHPG and HPMPC, the increase
in the amount of active forms of the drugs was linearly proportional to the
increase in concentration.

Effect of multiplicity of infection (MOl) on
drug phosphorylation
Cells were infected with resistant or sensitive virus at multiplicities of
infection (MOI) of 3.0, 1.0, 0.3, or 0.1, and treated with media containing DHPG at
10 J..!M or HPMPC at 1.0 J..!M for 24 h. In the cells treated with DHPG, the
amounts of DHPGppp produced by cells infected with both strains of virus were
almost identical to each other and the uninfected control. The amount of
DHPGppp did not increase until the MOl reached 3.0 PFU I cell. The resistant
sample had 0.228 pmol/106 cells and the sensitive sample had 0.235 pmol/106
cells. The uninfected control produced 0.146 pmol/106 cells (Fig. 6).
The cells treated with HPMPC followed a similar pattern. There was a
slow increase in the amount of HPMPCpp produced by the infected cells as MOl
increased, and the amounts produced by the cells infected with the two virus
strains were roughly the same. At an MOl of 3.0, the amount of HPMPCpp
produced reached 0.033 pmol/106 cells for the resistant infection, 0.024
pmol/106 cells for the sensitive infection, as compared to 0.016 pmol/106 cells
for the uninfected control (Fig. 7). It appears there was no significant difference
in the metabolism of the compounds in cells infected with sensitive and resistant
viruses when the MOl was increased.
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24-hour time-course experiment
In this experiment, the cells were infected with resistant, sensitive, or no

virus at an MOl of 1.0. The cells were incubated for 24 h, with samples being
harvested at 1, 2, 4, 6, 12, and 24 h postinfection. For cells treated with 10 ).J.M
DHPG, the metabolic data produced a linear curve. The amounts of DHPGppp
at 1 h postinfection was 0.008 pmol/106 cells for the resistant virus, 0.008
pmol/106 cells for the sensitive virus, and 0.003 pmol/106 cells for the
uninfected controls. At 24 h, these totals had increased to 0.150 pmol/106 cells,
0.152 pmol/106 cells, and 0.100 pmol/106 cells, respectively (Fig. 8).
With 1.0 ).J.M HPMPC, the metabolic data produced a sigmoidal curve.
The rate of production of HP:MPCpp increased slowly unti16 h postinfection,
when most of the production occurred. At 1 h postinfection, the amounts of
HPMPCpp for all three samples were less than 0.001 pmol/106 cells. This had
increased to only 0.003 pmol/106 cells for all samples at 6 h postinfection. By 12
h postinfection, the amounts of HP:MPCpp had increased sharply to 0.025
pmol/106 cells for the resistant and sensitive virus-infected samples and 0.019
pmol/106 cells for the uninfected control. The rate of increase then leveled off
again. At 24 h postinfection, the amounts of HP:MPCpp were 0.026 pmol/106 for
the resistant sample, 0.030 pmol/106 cells for the sensitive sample, and 0.019
pmol/106 cells for the control sample (Fig. 9).
There was no significant difference in the metabolism of the compounds
between the two strains of virus and the uninfected cells. With both DHPG and
HPMPC, the amount of active form of the drugs produced by the uninfected
controls began to level off after 12 h, while the amounts of active forms produced
by the two virus strains were higher but virtually identical to each other.
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Dephosphorylation and excretion of drugs
Cells were infected with resistant, sensitive, or no virus at an MOl of 1.0,
and incubated for 24 hours in media containing DHPG at 10 J1M or HPMPC at 1.0
~M.

After 24 h, the drug-containing media were removed, and drug metabolites

were quantified at different times thereafter. At 1 h radioactivity was detected in
the cell culture media, the amount of which remained at equilibrium for the rest
of the experiment. This indicated that the unphosphorylated form of each drug
was rapidly excreted from cells.

At the time of removal of the DHPG-containing medium, the amounts of
DHPGppp present were 0.150 pmol/106 cells for the resistant sample, 0.152
pmol/106 cells for the sensitive sample, and 0.125 pmol/1o6 cells for the
uninfected sample. After 24 h, these totals had been reduced by 90% to 0.015,
0.014, and 0.014 pmol/106 cells, respectively (Fig. 10). The catabolism curves for
the resistant and sensitive samples were nearly identical.
The HPMPCpp was dephosphorylated much more slowly than the
DHPGppp. At the time of drug removal, the amounts of HPMPCpp were 0.046
pmol/106 cells for the resistant sample, 0.045 pmol/106 cells for the sensitive
sample, and 0.051 pmol/106 cells for the uninfected sample. These totals did not
begin to decrease significantly until after 6 h postinfection; at that time, the
resistant sample had 0.048 pmol/106 cells, the sensitive sample had 0.043
pmol/106 cells, and the uninfected sample had 0.036 pmol/106 cells. By 24 h
postinfection, the totals were 0.022 pmol/ 106 cells for the resistant sample, 0.022
pmol/to6 cells for the sensitive sample, and 0.018 pmol/1o6 cells for the
uninfected sample. Thus, nearly 50% of the initial HPMPCpp was still present in
infected cells 24 h later. The catabolism curves for the resistant samples and the
sensitive samples closely followed each other (Fig. 11).
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The half-lives of DHPGppp HPMPCpp in the resistant, sensitive, and
uninfected samples were calculated using the InStat® statistical program. The
data for the dephosphorylation curves were entered and standard curves were
obtained for each sample. A value that represented 50% of the starting amount
of DHPGppp or HPMPCpp was entered and a time for that value was estimated.
The results are summarized in Table 4.

96-hour time-course metabolism experiment
To measure the differences in drug metabolism over 96 h, cells were
infected with resistant, sensitive, or no virus and treated with 10 ~M DHPG or
1.0 ~M HPMPC and incubated for 96 h. Cells infected with each virus type were
harvested at 24, 48, 72, and 96 hand the amounts of active forms of drugs were
measured.
In the case of DHPG, the total amounts of DHPGppp produced after 24 h
were 0.135 pmol/106 cells for the resistant sample, 0.152 pmol/106 cells for the
sensitive sample, and 0.120 pmol/106 cells for the control sample. At 96 h postinfection, the amounts had increased to 0.627 pmol/106 cells for the resistant
sample and 0.232 pmol/106 cells for the sensitive sample, and had decreased to
0.086 pmol/106 cells for the control sample (Fig. 12).
A similar effect was observed with HPMPC. At 24 h postinfection, the
amount of HPMPCpp was 0.030 pmol/106 cells for the resistant sample, 0.042
pmol/106 cells for the sensitive sample, and 0.022 pmol/106 cells for the control
sample~ After 96 h of incubation, the amounts were 0.241 pmol/106 cells in the

resistant sample, 0.118 pmol/106 cells in the sensitive sample, and 0.048
pmol/106 cells in the control sample (Fig. 13).
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Table 4
Half-lives (in hours) of DHPGppp and HPMPCpp in cells infected with resistant,
sensitive, or no virus
DHPG-treated
Resistant
Sensitive
Uninfecteu

9.8

10.8
11.8

HPMPC-treated
24.8
25.3
16.6

The progression of the cytomegalovirus infection over a period of 96 h
causes a concomitant increase in cytotoxicity. Because of this, each sample was
adjusted for cytotoxicity by determining cell numbers from the parallel sets of
flasks. At 96 h postinfection, the cell numbers for all sensitive and uninfected
samples were between 64% and 78% of the 24-h cell totals. However, the cell
numbers for the DHPG and HPMPC-treated resistant samples were 47.5% and
41.7%, respectively.

Virus yield results for 96-hour assay
To explain why phosphorylation continued to increase in the cells infected
with the resistant virus, a virus-yield assay over a period of 96 h was performed.
This was done to support the hypothesis that the increase in the levels of
DHPGppp and HPMPCpp in resistant-infected cells was related to virus
production.
The resistant virus was able to grow when treated with either 10 ~M
DHPG pr 1.0 J.LM HPMPC. The rates of growth were remarkably similar,
although the virus titers were about 2-fold higher in the DHPG-treated cells. At
24 h pos tinfection, the titer from the DHPG-treated cells was 6.6 X 1o3 PFU I ml,
the titer from the HPMPC-treated cells was 9.0 X 103 PFU /ml, and the titer from
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the untreated cells was 7.5 X 103 PFU /ml. At 48 h, the resistant virus titers had
jumped over 10-fold in the treated cells and over 100-fold in the untreated cells.
Between 48 and 72 h postinfection, the titers continued to increase rapidly, and
between 72 and 96 h postinfection the titers began to level off. At 96 h
postinfection, the resistant virus titers were 8.9 X 105 PFU/ml from the DHPGtreated cells, 3.5 X 105 PFU /ml from the HPMPC-treated cells, and 2.9 X 106
PFU /ml for the placebo-treated sample (three to nine times higher than the drugtreated cells). Although the rate of increase of the virus titers had slowed during
the final24 h of the experiment, they still increased during that time (Figs. 14, 15).
The sensitive virus grew in media containing DHPG and HPMPC at a
similar rate as the resistant virus for the first 24 h after infection. At 24 h
postinfection, the titers from the DHPG- and HPMPC-treated cells were actually
higher than those of the corresponding cells of the resistant virus, at 2.7 X 104
PFU/ml and 3.9 X 104 PFU/ml, respectively. However, by 72 h postinfection the
titers had began to drop in the HPMPC-treated cells, and the DHPG-treated titer
had increased only slightly. By 96 h postinfection, both the DHPG- and HPMPCtreated samples had dropped in titer. Final titers for the sensitive virus samples
were 9.0 X 104 PFU /ml from the DHPG-treated cells and 6.7 X 104 PFU /ml from
the HPMPC-treated cells (Figs. 14, 15). In contrast, the placebo-treated titer was
2.8 X107 PFU /ml, and it had increased logarithmically throughout the
experiment.
In summary, a general pattern of infection emerged during the 4-day
course of the experiment. The resistant virus continued to grow in spite of
antiviral treatment, although the rate of growth was slow. The treated sensitive
virus grew more quickly at first, but the treatment soon caused a drop in virus
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titers by 72 h postinfection. The placebo-treated sensitive virus continued to
grow throughout the experiment.

Correlation of drug phosphorylation
to virus titers
Upon comparing the 96-h phosphorylation data with the 96-h virus yield
data (Figs. 12-15), a striking similarity was noted between the phosphorylation
curves for the resistant-infected cells and the virus production curves from
similar samples. In both the DHPG and HPMPC-treated cells, the data curve of
the amounts of active form of the compounds closely matched the virus titers
obtained in the 96-h virus time course. In both cases, the resistant-infected cells
continued to produce phosphorylated drug/progeny virus for the entire
experiment, while the amounts of drug/virus produced by the sensitive infected
cells began to drop or level off after 48 h postinfection.
To test this relationship, r-and r2-values for the two curves were
calculated using the InStat® program. These values are tests of corellation for
linear regression, which is used to calculate the relationship between two
different sets of data. The closer the r-value is to 1.0, the more the two sets of
data are related, and the further the r-value is from 1.0, the less they are related.
(Two data sets that produce a curve with a slope of 1.0 are directly related.) The
r2-value is simply the square of the r-value, and is a more robust test of
significance. The same tests were performed for the sensitive-infected cell data,
and the results are shown in Table 5.
The correlation between the production of DHPGppp and HPMPCpp by
resistant-infected cells and virus production is strong. Two-tailed t-tests of the rvalue showed significance of p<0.02 for the HPMPC-treated samples and p<0.005
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for the DHPG-treated samples. This is not surprising, since the resistant virus
continued to grow during the treatment, and any increase in resistant virus was
expected to stimulate cellular kinases to phosphorylate more DHPGppp or
HPMPCpp. The correlation between virus production and drug phosphorylation
by the cells infected with sensitive virus is much weaker and was not found to be
significant by t-test of r-values. This is probably due to the fact that virus
production was inhibited as the production of DHPGppp or HPMPCpp
increased.
Table 5
Correlation between 96-hour virus production curves and 96-hour
phosphorylation curves in cells infected with resistant or sensitive virus and
treated with 10 ~M DHPG or 1.0 ~M HPMPC

r-value
r2-value
ap<O.OOS
bp<0.02

DHPG,
sensitive
0.7445
0.5543

10~M

resistant
0.996oa
0.992oa

HPMPC, 1.0 ~M
sensitive
resistant
0.9706b
0.6416
o.942ob
0.4117
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DISCUSSION
In these studies it was first demonstrated that a plaque-purified virus
derived from the GCV-r strain of MCMV (Smee et al., 1995) was resistant to
DHPG, HPMPC, and foscarnet (Table 1). This was followed up by a virus
growth study over time in which resistant and sensitive viruses were propagated
in 10 ~M DHPG of 1.0 ~M HPMPC. During the virus-yield experiment (Figs. 14,
15), the resistant virus continued to grow, albeit more slowly than the sensitive
"wild-type" strain. After 96 h, the virus titer in the resistant sample treated with
10 ~M DHPG was 10-fold greater than the titer in the flask infected with the
sensitive sample (Fig. 14), while a similar relationship was observed in the flask
treated with 1.0 ~M HPMPC, although the resistant titer was only five times
greater (Fig. 15). These results confirm the ability of the resistant strain to grow
in the presence of the two compounds.
The experiments measuring the phosphorylation of DHPG and HPMPC
showed that there is no significant difference in the amount of active forms of the
drugs produced in infected cells by the resistant and sensitive viral strains. The
exte t of drug phosphorylation in resistant virus-infected, sensitive virusinfected, and uninfected cells was very similar (Figs. 8, 9). Throughout all the
experiments the uninfected samples normally had lower levels of triphosphate
production. However, the levels of DHPGppp or HPMPCpp produced by the
resistant, sensitive, and uninfected samples were dissimilar only after 24 h of
incubatjon. At earlier time points, the levels produced by the three samples
were, in many cases, identical. It appears that there is no metabolic mechanism
during the first 24 h of infection, which would account for viral resistance to
DHPG and HPMPC. In fact, after 96 h of incubation, there was much more
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DHPGppp and HPMPCpp produced in the resistant-infected cells than in the
sensitive-infected cells.
A similar observation is made with the dephosphorylation data. The
dephosphorylation curves for the three infection categories show that the drugs
are dephosphorylated at the same rate, and the half-lives of DHPGppp and
HPMPCpp in cells infected with both types of virus are nearly equal (Figs. 10, 11;
Table 4). In addition, the amounts of active form of each drug after 24 hare the
same for the resistant and sensitive virus. There appears to be no mechanism
that would allow the resistant virus to catabolize the active forms of the drugs
more rapidly than the cells infected with the sensitive virus or the uninfected
cells.
Changing the parameters of multiplicity of infection (MOl) and the
concentration of the compound did not appear to demonstrate any significant
differences in drug phosphorylation in cells infected by the two strains of virus.
If the sensitive virus encoded a unique drug-phosphorylating enzyme, and

resistance to DHPG and HPMPC was due to a mutation in this enzyme, one
might have observed a major difference in phosphorylation rates in cells infected
with this virus as the MOl increased. The slight enhancement in drug
phosphorylation correlated with increasing MOl is consistent with the known
observation that host cell enzyme activity is stimulated by cytomegalovirus
infection (Stinski, 1990).
In light of the results from the virus yield experiment, which showed that
the resistant strain continues to produce virus over the course of the infection, the
results of the 96-h metabolic experiment are expected: The resistant virus would
of course continue to stimulate host cell kinases to produce active forms of the
drug, since the virus is less sensitive to inhibition by those compounds. The
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sensitive virus, on the other hand, would eventually stimulate the cells to
produce enough active compounds that they would inhibit further virus
production. The strong correlation between the 96-h virus production curve for
the resistant virus and the 96-h drug phosphorylation curve supports the view
that the infection stimulates phosphorylation. In addition, since viral infection
stimulates host cell enzymes (Stinski, 1990), this explains why the uninfected
cells produced the least amount of phosphorylated drugs.
As mentioned previously in this thesis, viral resistance to drugs such as
DHPG and HPMPC may be the result of two general mechanisms: decreased
phosphorylation of the parent compound in infected cells, or reduced ability of
the compound to inhibit the viral DNA polymerase (Sullivan et al., 1993). These
experiments were performed to study the possibility that the resistance of the
mutant strain was due to a change in a viral enzyme that would cause a decrease
in drug phosphorylation in infected cells. Since drug phosphorylation was not
reduced in cells infected with the resistant virus, this strengthens the second
hypothesis that resistance is due to a mutation in the viral DNA polymerase.
Another piece of data implicating the viral DNA polymerase in drug
resistance is that the resistant strain of virus is not only resistant to drugs
requiring phosphorylation (DHPG, HPMPC), but also to a drug that does not
require phosphorylation (foscarnet). Foscarnet can exert its antiviral effect
without modification (Oberg, 1989). Thus, resistance is most likely due to
diminished affinity of the MCMV DNA polymerase to these drugs, possibly the
result of a point mutation that affects the enzyme's active site.
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CONCLUSION
C127I cells infected with a drug-resistant strain of murine
cytomegalovirus do not phosphorylate DHPG or HPMPC differently than cells
infected with the sensitive cytomegalovirus strain or uninfected C127I cells.
Metabolism and catabolism of DHPG and HPMPC in resistant, sensitive, and
uninfected cells were essentially similar during the first 24 h of infection. The
phosphorylation of DHPG and HPMPC by the resistant and sensitive virus
strains was not significantly affected by changing the multiplicity of infection or
concentration of compound. Cells infected with the resistant strain of virus
continued to produce virus when treated with DHPG or HPMPC at
concentrations that caused the sensitive strain to eventually stop replicating.
Production of virus in the resistant strain was closely correlated with production
of the active forms of DHPG and HPMPC. This correlation was also evident in
cells infected with the sensitive strain of virus, but was not as strong. These data
are consistent with the fact that cytomegalovirus infection stimulates host cell
kinase activity, thus indirectly enhancing drug phosphorylation. Based on these
results, the mode of resistance in the mutant strain of virus does not appear to be
due to differences in the ability of cells infected with this virus to metabolize or
catabolize DHPG or HPMPC. This implies that a mutation in the viral DNA
polymerase may be responsible for drug resistance.
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